HIV-1 DNA and RNA kinetics in primary HIV infection
- PMID: 12003174
HIV-1 DNA and RNA kinetics in primary HIV infection
Abstract
Background: HIV-1 reservoir is early established during PHI. It is reduced, but not extinguished by early therapy: DNA containing cells are still detectable after months of successful viremia suppression. To define the best method to measure low level viral replication, we determined the extent of HIV reservoir in 11 acutely infected patients and evaluated how it is renewed even during successful treatment.
Methods: Eleven acutely infected HIV patients were included in the study. Three where not treated with antiretroviral drugs while 8 underwent early aggressive antiretroviral treatment (HAART) which, in 3 cases, was associated to cyclosporin A (CsA) administration. HIV viremia was monitored by commercially available methods while HIV-DNA and cellular RNA quantitation were obtained by in house PCR and RT-PCR respectively, in the gag region.
Results: Significant CD4 recover and HIV viremia suppression were reached in a mean period of three to six months in all treated patients. The course of the HIV-DNA and of cellular HIV RNA reduction showed a similar trend. This variation was slower, if compared to plasma viremia and never reached undetectable levels, justifying the rebound of viremia observed at therapy interruption.
Conclusions: These data suggest and confirm that complete abolition of viral replication is not achieved and viral reservoir may be re-expanded even after short term rebound of viremia. Scheduling of possible structured therapy interruption should be designed based on multiple virological parameters and on the individual characteristics of the patients.
Similar articles
-
Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.J Clin Virol. 2005 Dec;34(4):257-67. doi: 10.1016/j.jcv.2005.02.015. Epub 2005 Apr 18. J Clin Virol. 2005. PMID: 16286049
-
Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.J Med Virol. 2007 Aug;79(8):1047-54. doi: 10.1002/jmv.20895. J Med Virol. 2007. PMID: 17597482
-
Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.J Med Virol. 2004 Jul;73(3):350-61. doi: 10.1002/jmv.20098. J Med Virol. 2004. PMID: 15170628
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
-
Primary HIV infection in infants: impact of highly active antiretroviral therapy on the natural course.J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):53-7. J Biol Regul Homeost Agents. 2002. PMID: 12003175 Review.
Cited by
-
Incident Kaposi sarcoma during the expansion of antiretroviral therapy eligibility in Nigeria: a retrospective cohort study.BMC Cancer. 2023 Sep 21;23(1):890. doi: 10.1186/s12885-023-11402-3. BMC Cancer. 2023. PMID: 37735371 Free PMC article.
-
Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):65-76. doi: 10.1097/QAI.0b013e3181900141. J Acquir Immune Defic Syndr. 2009. PMID: 19295336 Free PMC article.
-
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.PLoS One. 2012;7(8):e43754. doi: 10.1371/journal.pone.0043754. Epub 2012 Aug 31. PLoS One. 2012. PMID: 22952756 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials